| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $938,335 ) |
| | 2025 | 2025 | SANSIMEON INC | 1209 N ORANGE ST | WILMINGTON | DE | 19801 | NEW CASTLE | USA | R44GM149003 | A Uniquely Scalable Platform for Sequencing Tens of Millions of Single Cells from Complex Clinical Samples with a Streamlined Workflow | 000 | 2 | NIH | 8/8/2025 | $938,335 |
| | 2025 | 2023 | SANSIMEON INC | 1209 N ORANGE ST | WILMINGTON | DE | 19801 | NEW CASTLE | USA | R43GM149003 | A Uniquely Scalable Approach to Sequence Tens of Millions of Single Cells Without Compromising Performance | 000 | 1 | NIH | 3/12/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $399,369 ) |
| | 2024 | 2024 | SANSIMEON INC | 1209 N ORANGE ST | WILMINGTON | DE | 19801-1120 | NEW CASTLE | USA | R43HG013446 | A Uniquely Scalable Approach to Single Cell Sequencing for the Development of Next Generation Cell Therapies | 000 | 1 | NIH | 2/23/2024 | $399,369 |
|
| Issue Date FY: 2023 ( Subtotal = $275,628 ) |
| | 2023 | 2023 | SANSIMEON INC | 1209 N ORANGE ST | WILMINGTON | DE | 19801-1120 | NEW CASTLE | USA | R43GM149003 | A Uniquely Scalable Approach to Sequence Tens of Millions of Single Cells Without Compromising Performance | 000 | 1 | NIH | 7/26/2023 | $275,628 |
|
|
